Visceral Adiposity and Sarcopenic Visceral Obesity are Associated with Poor Prognosis After Resection of Pancreatic Cancer

Abstract

Visceral adiposity and sarcopenic visceral obesity, as well as low muscle mass and quality, were closely associated with mortality and recurrence after resection of pancreatic cancer.

Impact of intramuscular adipose tissue content on short- and long-term outcomes of hepatectomy for colorectal liver metastasis: a retrospective analysis

“…Recently, the concept of sarcopenic obesity has been proposed. It has been suggested that sarcopenic obesity is a poor prognostic factor in several malignant diseases [25,26]. In the present study, BMI was higher in the H group than in the N group; thus, the proportion of body fat might also be higher in the H group, suggesting that a high IMAC may be an index of sarcopenic obesity.…”

Assessing skeletal muscle radiodensity by computed tomography: An integrative review of the applied methodologies

“… 1, Antoun et al (2013); 2, Martin et al (2013); 3, Akahori et al (2015); 4, Aust et al (2015); 5, Fujiwara et al (2015); 6, Malietzis et al , (2015); 7, Malietzis et al , (2016); 8, Malietzis, Johns, et al (2016); 9, Malietzis, Lee, et al (2016); 10, Boer et al (2016); 11, Cushen et al (2016); 12, Hayashi et al (2016); 13, Kumar et al (2016); 14, Pędziwiatr et al (2016); 15, Rollins et al (2016); 16, Sjøblom et al (2016); 17, Tamandl, Pedley, Hoffmann, Fox, and Murabito (2016); 18, Atlan et al (2017); 19, Bye et al (2017); 20, Chu et al (2017); 21, Daly et al (2017); 22, Daly, Ní Bhuachalla, et al (2018); 23, Kubo, Naito, Mori, Osawa, and Aruga (2017); 24, Loumaye et al (2017); 25, Okumura et al (2017a); 26, Okumura et al (2017b); 27, Rier et al (2017); 28, Rier et al (2018); 29, Shachar, Deal, Weinberg, Williams, et al (2017); 30, Shachar, Deal, Weinberg, Nyrop, et al (2017); 31, Van Rijssen et al (2017); 32, van Roekel et al (2017); 33, Williams et al (2017); 34, Williams et al (2018); 35, Choi et al (2018); 36, Deng et al (2018); 37, Ní Bhuachalla et al (2018); 38, Rodrigues and Chaves (2018); 39, Silva de Paula et al (2018); 40, Souza et al (2018); 41, Versteeg et al (2018); 42, Charette et al (2019); 43, Kiss et al (2019); 44, Zhang et al (2018); 45, Dohzono, Sasaoka, Takamatsu, Hoshino, and Nakamura (2019); 46, van Baar et al (2018); 47, Atasevenet et al (2018); 48, Martin et al (2018); 49, Stretch et al (2018); 50, van Dijk et al (2018); 51, van Vugt, Gaspersz, et al (…”

“…1, Mayer et al (1989); 2, Goodpaster, Kelley, et al (2000); 3, Hicks et al (2005a); 4, Hicks et al (2005b); 5, Komiya et al (2006); 6, Laroche and Cintas (2010); 7, Anderson et al (2013); 8, Anderson et al (2014); 9, Antoun et al (2013); 10, Miljkovic et al (2013); 11, Therkelsen et al (2013); 12, Therkelsen et al (2016); 13, Kim et al (2014); 14, Akahori et al (2015); 15, Aust et al (2015); 16, Malietzis et al (2015); 17, Malietzis, Currie, et al (2016); 18, Malietzis, Johns, et al (2016); 19, Malietzis, Lee, et al (2016); 20, Cushen et al (2016); 21, Hayashi et al (2016); 22, Kumar et al (2016); 23, Looijaard et al (2016); 24, Montano‐Loza et al (2016); 25, Rollins et al (2016); 26, Wang et al (2016); 27, Atlan et al (2017); 28, Azuma et al (2017); 29, Bye et al (2017); 30, Erlandson et al (2017); 31, Locke et al (2017); 32, Loumaye et al (2017); 33, Okumura et al (2017b); 34, Rier et al (2017); 35, Rier et al (2018); 36, Shachar, Deal, Weinberg, Williams, et al (2017); 37, Shachar, Deal, Weinberg, Nyrop, et al (2017); 38, van Roekel et al (2017); 39, Williams et al (2017); 40, Williams et al (2018); 41, Choi et al (2018); 42, Rodrigues and Chaves, (2018); 43, Silva de Paula et al (2018); 44, Souza et al (2018); 45, Versteeg et al (2018); 46, Charette et al (2019); 47, Kiss et al (2019); 48, Zhang et al (2018); 49, Coats et al (2018); 50, Vella et al (2018); 51, Dohzono et al (2019); 52, van Baar et al (2018); 53, ...…”

“… 1, Mayer et al (1989); 2, Goodpaster, Kelley, et al (2000); 3, Ricq and Laroche, (2000); 4, Hicks et al (2005a); 5, Hicks et al (2005b); 6, Komiya et al (2006); 7, Anderson et al (2013); 8, Anderson et al (2014); 9, Antoun et al (2013); 10, Martin et al (2013); 11, Miljkovic et al (2013); 12, Akahori et al (2015); 13, Aust et al (2015); 14, Fujiwara et al (2015); 15, Malietzis et al (2015); 16, Malietzis, Currie, et al (2016); 17, Malietzis, Johns, et al (2016); 18, Malietzis, Lee, et al (2016); 19, Boer et al (2016); 20, Cushen et al (2016); 21, Hayashi et al (2016); 22, Kumar et al (2016); 23, Looijaard et al (2016); 24, Montano‐Loza et al (2016); 25, Pędziwiatr et al (2016); 26, Rollins et al (2016); 27, Sjøblom et al (2016); 28, Tamandl et al (2016); 29, Wang et al (2016); 30, Atlan et al (2017); 31, Bye et al ; (2017); 32, Chu et al (2017); 33, Daly et al (2017); 34, Daly, Ní Bhuachalla, et al (2018); 35, Erlandson et al (2017); 36, Kubo et al (2017); 37, Locke et al (2017); 38, Loumaye et al (2017); 39, Okumura et al (2017a); 40, Okumura et al (2017b); 41, Rier et al (2017); 42, Rier et al (2018); 43, van Grinsven et al (2017); 44, Van Rijssen et al (2017); 45, van Roekel et al (2017); 46, Choi et al (2018); 47, Matsumoto et al (2018); 48, Ní Bhuachalla et al (2018); 49, Souza et al (2018); 50, Versteeg et al (2018); 51, Graffy et al (2019); 52, Charette et al (2019); 53, Kiss...…”

Sarcopenic Obesity in Cancer Patients: Focus on Pathogenesis

“…The alteration in body composition also makes an impaired response to chemotherapy and radiation therapy in a variety of cancers, making treatments more difficult in these patients. In a retrospective study of pancreatic cancer patients, sarcopenic obesity is associated with lower overall survival and recurrence-free survival [7,17,[73][74][75][76][77][78] Multiple studies of different cancer patients conclude sarcopenic obesity as an independent risk factor on clinical outcomes and overall survival after surgical resection [28,79]. Sarcopenic obesity is also seen as an independent risk factor of mortality in lung, prostate, and GI cancer patients with the locally advanced or metastatic disease [11,[80][81][82][83].…”